Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion

Trial Profile

Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 09 May 2017

At a glance

  • Drugs Larotrectinib (Primary)
  • Indications Cancer
  • Focus Expanded access; Therapeutic Use
  • Sponsors Loxo Oncology
  • Most Recent Events

    • 09 May 2017 According to a Loxo Oncology media release, data from this trial (n =1) has been presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting.
    • 24 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top